RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced today that it has completed a registered offering in which it raised a total of $15 million in gross proceeds from the sale of common stock units. The units were priced at $0.70 per unit which at closing separated into a share of PolyMedix common stock and a five year warrant to purchase a share of PolyMedix common stock at $1.00. Emerging Growth Equities of King of Prussia, PA, Fordham Financial of New York, and Carter Securities of New York placed the units sold in the offering. The investors in the transaction were both institutional as well as individual investors.
